Felix Chu
Impact in
- Hepatology top 2%
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
Papers in
-
- Liver physiology and pathology 3
- Co-authors
- Belinda CancillaFrauke BentzienYongchang ShiF. Michael YakesAlison JolyStefan EngstPeiwen YuFawn Qian
- Journals
- Molecular Cancer Therapeutics (3 papers)The Laryngoscope (3 papers)iScience (1 paper)Clinical Cancer Research (1 paper)mAbs (1 paper)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Felix Chu
18 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Hepatology 324
- Oncology 632
- Otorhinolaryngology 74
- Pulmonary and Respiratory Medicine 539
- Cancer Research 238
Countries citing papers authored by Felix Chu
This map shows the geographic impact of Felix Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Chu more than expected).
Fields of papers citing papers by Felix Chu
This network shows the impact of papers produced by Felix Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Chu. The network helps show where Felix Chu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Felix Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2018 | 36 | |
| 3 | 2017 | 26 | |
| 4 | 2016 | 6 | |
| 5 | 2015 | 0 | |
| 6 | 2015 | 10 | |
| 7 | 2013 | 102 | |
| 8 | 2013 | 10 | |
| 9 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth Hit paper breakdown → | 2011 | 1036 |
| 10 | 2010 | 160 | |
| 11 | 2009 | 4 | |
| 12 | 2005 | 81 | |
| 13 | 1998 | 8 | |
| 14 | 1995 | 14 | |
| 15 | 1993 | 11 | |
| 16 | 1993 | 11 | |
| 17 | 1988 | 27 | |
| 18 | 1988 | 63 | |
| 19 | 1986 | 76 |
About Felix Chu
Felix Chu is a scholar working on Otorhinolaryngology, Hepatology, Oral Surgery, Oncology and Periodontics, having authored 19 papers that have together received 1.7k indexed citations. Recurring topics across this work include Liver physiology and pathology (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cancer Mechanisms and Therapy (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Ear and Head Tumors (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Oral and Maxillofacial Pathology (2 papers). The work is most often cited by research in Hepatology (324 citations), Oncology (632 citations), Otorhinolaryngology (74 citations), Pulmonary and Respiratory Medicine (539 citations) and Cancer Research (238 citations). Felix Chu has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Belinda Cancilla, Frauke Bentzien, Yongchang Shi, F. Michael Yakes, Alison Joly, Stefan Engst, Peiwen Yu, Fawn Qian, Jason Chen and Alexander Laird. Their work appears in journals such as Molecular Cancer Therapeutics, The Laryngoscope, iScience, Clinical Cancer Research and mAbs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.